Multiple lines of evidence suggest that calcium/calmodulin-dependent kinase II ␣ (CaMKII␣) plays an important role in the spinal dorsal horn in nociceptive models of chemical, inflammatory and nerve injury. Moreover, CaMKII␣ phosphorylates the vanilloid receptor type 1 (TRPV1), thereby regulating vanilloid agonist binding to the receptor. Herein, we have explored a possible interaction of CaMKII␣ activity with the TRPV1 receptor in rat trigeminal ganglion (TG) neurons in vitro. Inhibition of CaMKII␣ with KN-93 (5 M) inhibited capsaicin (CAP)-and n-arachidonoyl-dopamine (NADA)-evoked calcitonin gene-related peptide (CGRP) release effectively decreasing the E max for both compounds. This effect was not mimicked by the inactive compound KN-92 (5 M), indicating that the effect was mediated by CaMKII␣ inhibition. CAP also stimulated a significant ∼50% increase in autophosphorylation of CaMKII␣ at Thr 286/287 . Immunocytochemistry for phospho-CaMKII␣ indicated that this effect specifically occurred in TRPV1-positive TG neurons. These findings indicate that phophoCaMKII␣ is likely to play a role in presynaptic primary afferents in animal models of nociceptive hypersensitivity and provide support for CaMKII␣ modulation of TRPV1 activity in sensory neurons. © 2005 Elsevier Ireland Ltd. All rights reserved.
ter release [6] , likely through phosphorylation of vesicular release proteins [20] .
Recently, a role for CaMKII␣ has emerged in nociception, wherein CaMKII␣ is believed to be involved in central sensitization [27] . CaMKII␣ is expressed by PKC-gammaexpressing interneurons of lamina II in the dorsal horn [28] . CaMKII␣ is also expressed by vanilloid receptor type 1 (TRPV1 [4] )-immunoreactive dorsal root ganglion (DRG) neurons. Moreover, CaMKII␣ is expressed in calcitonin gene-related peptide (CGRP)-and TRPV1-immunoreactive neurons of the trigeminal ganglion (TG [14] ). CaMKII␣ is also transported to central and peripheral terminals [3] of nociceptors, and it colocalizes to both substance P (SP)-immunoreactive and isolectin B 4 -binding afferent terminals in the dorsal horn [14] . Dorsal horn CaMKII␣ protein levels increase following intraplantar formalin injection [18] , and CaMKII␣ protein in the medullary dorsal horn is like-wise increased following nerve injury to the inferior alveolar nerve wherein mechanical allodynia (as measured by escape behavior) is alleviated by CaMKII␣ inhibition [21] . Peripheral CaMKII␣ immunoreactivity also increases following complete Freund's adjuvant (CFA)-induced inflammation [3] . CaMKII␣ appears to be involved in spinal LTP, as inhibition of CaMKII␣ in identified nociceptive dorsal horn neurons blocks the development of high-frequency stimulation-induced LTP [22] . Finally, autophosphorylationdeficient CaMKII␣ mutant mice display deficiencies in ongoing nociceptive responses in the formalin model, leading to the hypothesis that CaMKII␣ is primarily involved in spontaneous nociceptive responses [28] .
CaMKII␣ appears to be particularly involved in the capsaicin (CAP) pain model and has been implicated in the modulation of the capsaicin receptor, TRPV1. Thus, spinal CaMKII␣ protein and phospho-CaMKII␣ increase following intraplantar injection of capsaicin [9] . Moreover, spinal CaMKII␣ inhibition abrogates decreased exploratory behavior, central sensitization of nociceptive dorsal horn neurons and GluR1 receptor phosphorylation [9] following intraplantar CAP injection. Intracolonic CAP injection-stimulated delivery of dorsal horn GluR1 receptors to the membrane is also blocked by inhibition of CaMKII␣ [10] . In DRG neurons, CaMKII␣ has been implicated in the sensitization of TRPV1 responses induced by nerve growth factor (NGF [2] ), and CaMKII␣ directly phosphorylates the TRPV1 receptor at residues at which protein kinase A and C also phosphorylate TRPV1 [15] . Phosphorylation of TRPV1 by CaMKII␣ regulates the binding of vanilloid compounds to the receptor, and CaMKII␣ phosphorylation appears to be necessary for CAP-induced activation of TRPV1 [15] . Hence, CaMKII␣ is important for CAP actions at TRPV1 and CAP-induced central sensitization. However, it is unclear whether presynaptically activated CaMKII␣ might be involved in the effects of CAP injection. Here, we demonstrate that CAP stimulates CaMKII␣ phosphorylation in TG neurons and that inhibition of CaMKII␣ modulates CAP-evoked neuropeptide release from these neurons in vitro. These findings indicate that presynaptic effects of increased CaMKII␣ activity might be involved in the effects of CAP injection in vivo.
To study CAMKII␣ phosphorylation state and the effects of inhibition of CaMKII␣ on neuropeptide release specifically in sensory neurons, we utilized cultured TG neurons from adult (250-300 g) rats (Sprague-Dawley, Charles River). All animal procedures were approved by The University of Texas Health Science Center at San Antonio Animal Care and Use Committee and were in accordance with NIH guidelines. TG neurons were cultured as previously described [23] , at a density of ∼5000 neurons/well in 48-well plates for CGRP release experiments and at a density of ∼40,000 neurons/well in 6-well plates for phospho-CaMKII␣ assessment. CGRP release assays and radioimmunoassays were performed as described previously [23] . For immunocytochemistry (ICC, method described in [24] ), neurons were grown on glass coverslips in 12-well plates at a density of ∼500 neurons/well. Before assaying, all TG neuronal cultures were maintained for 5 days in DMEM media supplemented with 10% fetal bovine serum and 100 ng/ml NGF. The anti-phospho-CaMKII␣ (Thr 286/287 , 1:1000 for ICC and Western blotting) antibody and anti-CaMKII␣ (1:1000 for Western blotting) antibody were from Chemicon. Both CaMKII␣ antibodies recognize only a single band at 50 kDa corresponding to the molecular weight of CaMKII␣ by Western blot. The anti-TRPV1 antibody (1:2000) was from Neuromics (see [12] for details on antibody specificity). Western blotting was performed by SDS-PAGE, and phosphoCaMKII␣ levels were standardized to total CaMKII␣ expression.
We first explored the effect of CaMKII␣ inhibition on CAP-evoked CGRP release from TG neurons. TG neurons were preincubated for 10 min with the CaMKII␣ inhibitor KN-93 (5 M) or vehicle and then exposed to CAP (0.3 nM-30 M) for 10 additional minutes in the continued presence of KN-93. CAP-evoked CGRP release concentration-response functions showed a U-shaped curve, wherein the downward phase of the curve is likely due to rapid desensitization of TRPV1 by higher concentrations of CAP. KN-93 had no effect on the upward EC 50 for CAP-evoked CGRP release but did significantly reduce the E max measured at 100 nM (Fig. 1) . KN-93 also significantly inhibited 300 and 600 nM CAP-evoked CGRP release (Fig. 1) . The CaMKII␣-inactive, but structurally related compound KN-92 (5 M) had no effect on CAP-evoked release at concentrations of CAP inhibited by KN-93 (Fig. 1) . Because the largest effect of KN-93 on CAP-evoked release was observed at 300 nM CAP, we tested whether this concentration of CAP was capable of stimulating CaMKII␣ autophosphorylation at Thr 286/287 , a requisite step in CaMKII␣ activation. When TG neurons were exposed to 300 nM CAP for 10 min, a significant, ∼50% increase in phospho-CaMKII␣ was observed ( Fig. 2A and B) . We next utilized the same concentration and time exposure of CAP in ICC studies to examine whether the phospho-CaMKII␣ occurred specifically in TRPV1-immunoreactive neurons. As shown in Fig. 2C , phospho-CaMKII␣ immunoreactivity was evident in TRPV1-positive TG neurons, while no above background immunoreactivity was noted in TRPV1-negative neurons. Due to the inherent difficulties in accurately quantifying immunoreactivity signals, no attempt was made to assess increases in phospho-CaMKII␣ in these neurons; however, these data indicate that the increases in phospho-CaMKII␣ observed by Western blot were likely to have occurred specifically in TRPV1-immunoreactive neurons.
In addition to the prototypic TRPV1 agonist CAP, several endogenous TRPV1 agonists have been identified. Of particular interest is the endogenous cannabinoid/vanilloid ligand n-arachidonoyl dopamine (NADA), which exhibits greater potency than other endogenous cannabinoid/vanilloid agonists, such as anandamide. To evaluate whether KN-93-induced inhibition of CGRP release also occurs with other TRPV1 agonists, we examined the effect of KN-93 on NADA (10 nM-30 M)-evoked CGRP release. KN-93 (5 M) pre- treatment inhibited NADA-evoked CGRP release at 3 and 10 M (Fig. 3) , effectively decreasing the E max for NADAevoked CGRP release. Concentrations of NADA at and above 30 M were not utilized because we have previously shown non-TRPV1 mediated effects of NADA on evoked CGRP release at these higher concentrations [23] .
We have demonstrated that CAP stimulates CaMKII␣ phosphorylation at Thr 286/287 in TRPV1-immunoreactive neurons. This is likely relevant to the in vivo CAP model, because previous studies have indicated that CaMKII␣ kinase activity plays an important role in the activation of downstream effectors, such as AMPA receptors, as well as in behavioral manifestations of the model [9] . Many of these effects have been attributed to postsynaptic actions of CaMKII␣ [9, 10] ; however, the present findings indicate that presynaptic actions might also be involved. In that regard, it has been shown that CaMKII␣ [28] and phospho-CaMKII␣ [17] are present in normal animals in presynaptic C-fiber terminals of the dorsal horn. CaMKII␣ plays a role in augmenting synaptic vesicle release through phosphorylation of proteins involved in vesicle fusion [20] . Moreover, the release of neuropeptides, especially SP [1] and CGRP [25] , is believed to play an important role in central sensitization, and is increased following peripheral inflammation [11] . To this end, we have also illustrated that CaMKII␣ inhibition is capable of inhibiting CAP-evoked CGRP release, particularly at higher CAP concentrations, and that CAP stimulates CaMKII␣ autophosphorylation in sensory neurons themselves. Our findings thus indicate that these presynaptic effects might be important with regard to dorsal horn CaMKII␣ inhibition in the CAP model.
CaMKII␣ has been implicated in regulating vanilloid binding to the TRPV1 receptor [15] . In this regard, there appears to be an interplay between calcineurin and CaMKII␣, wherein calcineurin is involved in regulating calciumsensitive desensitization through direct phosphatase activity [8] . CaMKII␣, on the other hand, appears to be involved in the resensitization of the TRPV1 receptor through rephosphorylation of residues required for vanilloid binding to the receptor [15] . There are numerous examples of opposing actions of CaMKII␣ and calcineurin on calciumpermeable ion channels (such as the ␣7 nicotinic receptor [19] ) and synaptic plasticity [26] and the balance of kinase to phosphatase activity appears to depend on local calcium concentrations [26] . We have demonstrated that inhibition of CaMKII␣ diminishes CAP-evoked CGRP release, especially at concentrations at which the CAP-evoked CGRP release concentration-response function illustrates a downward inflection. Insofar as CaMKII␣ inhibition shifts the CAP-evoked CGRP release concentration-response function toward greater desensitization (as measured by decreased CGRP release), the present finding supports the notion that CaMKII␣ is involved in resensitization of TRPV1, at least when CAP is the agonist utilized. Because we also observed an increase in phospho-CaMKII␣ with CAP treatment, calcium entry through TRPV1 itself might be involved in an autoregulatory loop through which CaMKII␣ becomes autophosphorylated and resensitizes TRPV1. Since both desensitization and resensitization of TRPV1 appear to involve calcium-dependent mechanisms, gaining a more complete understanding of how calcium signals mediate these distinct mechanisms might yield novel insight into how TRPV1 activity can be therapeutically modulated.
We have also demonstrated that CaMKII␣ inhibition attenuates NADA-evoked CGRP release. Since concentrations of NADA above 30 M have non-specific effects on evoked CGRP release [23] we were unable to examine desensitization effects in a manner analogous to that performed for CAP. However, CaMKII␣ inhibition reduced the E max for NADA-evoked CGRP release much as it did for CAP-evoked CGRP release. Other methods will be required, such as patch-clamp electrophysiology, to determine the effects of CaMKII␣ on NADA-induced TRPV1 desensitization/resensitization. The TRPV1 receptor plays an important role in inflammation-induced nociception [5] , and multiple lines of evidence suggest that endogenous agonists are involved in TRPV1-mediated nociception. Intrathecal and local peripheral administration of the TRPV1 antagonist A-425619 attenuated thermal hyperalgesia in the inflammatory CFA model and mechanical allodynia in the neuropathic sciatic nerve ligation model [13] . Moreover, spinal application of capsazepine inhibits A∂ and C-fiber-driven responses of spinal dorsal horn neurons [16] . NADA is an attractive candidate for this action due to its potency and efficacy at TRPV1 receptors. Additionally, central [9] and peripheral [3] CaMKII␣ appears to be involved in inflammation-induced nociception. Our observation that inhibition of CaMKII attenuates endogenous mediator activation of TRPV1-mediated sensory neuron activity (as measured by CGRP release) indicates that targeting CaMKII␣ interactions with TRPV1 might be an effective manner through which TRPV1-mediated nociception can be modulated.
In summary, we have provided evidence that CAP stimulates autophosphorylation of CaMKII␣ in sensory neurons and that pharmacological inhibition of CaMKII␣ reduces TRPV1-mediated CGRP release. These results suggest that presynaptic CaMKII␣ autophosphorylation is likely to contribute to increases in phospho-CaMKII␣ observed in the dorsal horn in the CAP inflammation model and support the proposed role of CaMKII␣ in regulation of TRPV1-mediated afferent activity.
